The estimated Net Worth of Gregory C Critchfield is at least 4.42 百万$ dollars as of 28 August 2009. Gregory Critchfield owns over 46,682 units of Myriad Genetics stock worth over 4,421,557$ and over the last 22 years Gregory sold MYGN stock worth over 0$.
Gregory has made over 9 trades of the Myriad Genetics stock since 2006, according to the Form 4 filled with the SEC. Most recently Gregory exercised 46,682 units of MYGN stock worth 413,603$ on 28 August 2009.
The largest trade Gregory's ever made was exercising 46,682 units of Myriad Genetics stock on 28 August 2009 worth over 413,603$. On average, Gregory trades about 9,282 units every 53 days since 2003. As of 28 August 2009 Gregory still owns at least 168,248 units of Myriad Genetics stock.
You can see the complete history of Gregory Critchfield stock trades at the bottom of the page.
Gregory's mailing address filed with the SEC is , , , , .
Over the last 22 years, insiders at Myriad Genetics have traded over 51,783,466$ worth of Myriad Genetics stock and bought 61,160 units worth 1,252,955$ . The most active insiders traders include Jerry S Lanchbury、Peter D Meldrum、Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of 563,312$. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth 270,500$.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: